URMD -- Huge market potential Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael G. Potter who wrote (36)	3/19/1997 12:35:00 AM
From: Stratajema	of 369

Michael. I think the most important point you mentioned is the issue of cost reimbursement under insurance policies and Medicare. And of course this issue also faces Rochester Medical. Without reimbursement I feel the ramp-up in demand could prove to be slow. One of the questions I have for Uromed is why are they waiting until next year to begin marketing the patch product that they recently acquired for $30MM. After paying a large sum for that FDA approved product I would think there would be more urgency to get the product manufactured. What ever the reasoning, it is a dangerous move on the part of management to wait and even more dangerous if they were willing to purchase the rights to the patch and not have the ability to generate revenue from it for over a year and half. Some have speculated that Uromed made the purchase to have control over a competing product. However, this strategy is dangerous IMHO. Perhaps you could pose this question again to Uromed to see if their story has changed. As a follow-up to my earlier post, I wanted to clarify that Uromed's Reliance product is also latex-free. The mainstream consumer is slowly learning why this designation is so important. Regards, David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next